BioCryst to Present at J.P. Morgan Healthcare Conf
Post# of 301275
RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's development programs at the 33 rd annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2015 at 9:00 a.m. Pacific Time.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm .
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, including BCX4161 and several second generation compounds, and BCX4430 , a broad spectrum viral RNA polymerase inhibitor. In December 2014, RAPIVAB TM (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, was approved by the FDA and is available to treat flu patients in the U.S. For more information, please visit the Company's website at www.BioCryst.com .
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm .
BCRXW
Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
(0)
(0)